News Article | May 10, 2017
This award follows our 1st place finish in the HRO Today Magazine’s 2017 Baker’s Dozen Award – Relocation, announced in March, and our 1st place at the European 2016 EMMA Awards in London last November, and our 2016 win in the Re:locate Magazine Awards for Best Relocation Management Company. “Once again, out of a crowded field of contestants, MSI is delighted to be recognized by one of the relocation industry’s leading organizations,” commented Timm Runnion, MSI’s CEO. “To be regularly seen, acknowledged and recognized as a leading provider of Global Talent Solutions and an innovator in our industry, is validation of our mission, vision and purpose as a company” Runnion added. It is our people, our own talent, with their constant and diligent focus on quality service, client/transferee experience, and positive and successful outcomes, that makes this all possible. We want to thank and recognize them for their efforts and this accomplishment.” MSI is a professional services organization dedicated to helping companies grow, compete, and globalize through the development and implementation of highly effective human capital strategies and the alignment of resources and services necessary to carry them out. Global corporations depend on our trusted expertise and managed services capabilities in the specialized areas of:
News Article | May 12, 2017
Receive press releases from Aspose Pty Ltd: By Email Use Enhanced GS1 Barcode Generation & Recognition in SQL Server Reporting Services Using Aspose.BarCode for SSRS APIs 17.4 It Aspose.BarCode for SSRS APIs 17.4.0 enhanced functionality of GS1 coded barcode. It allows developers to generate GS1 coded barcode according to AI specifications. New validators have been incorporated that can validate text code having only digits & complex AIs. API will throw an exception in case it fails to validate. Functionality of ExportToXml method has been improved. ExportToXml method now export dimension properties along with other properties of newly define barcode into XML file. Lane Cove, Australia, May 12, 2017 --( We are happy to announce the new release of Aspose.BarCode for Reporting Services 17.4.0. The major development in this release is the enhanced functionality of GS1 coded barcode. More often it is seem that GS1 code text contains complex combination of digits and letters. With Aspose.BarCode for SSRS 17.4, parsing and validation of those complex combinations is possible. Aspose.BarCode for SSRS allows developers to generate GS1 coded barcode according to AI (Application Identifier) specifications. New validators have been incorporated that can validate text code having only digits and complex AIs (combination of digits & letters). API will throw an exception in case it fails to validate. According to AI specification (ref: 703 AI, with letters – 324a, with more than 4 symbols) code text “(703)123” is incorrect. Aspose.BarCode will throw following exception if user tries to generate the barcode with EncodeTypes as GS1Code128. The following exception message will be displayed for such an incorrect barcode. Functionality of ExportToXml method has been improved. ExportToXml method now export dimension properties along with other properties of the newly define barcode into XML file. Below is the list of new and improved features added in this new release. • Improve GS1 parsing and validation • BarCodeBuilder allows to generate incorrect GS1 barcodes • Barcode generator accepts incorrect GS1 codetext • BarCodeBuilder.ExportToXml method is not exporting dimensions of the barcode in the XML file • Reorganize properties in Properties Window Newly added documentation pages and articles Some new tips and articles have now been added into Aspose.BarCode for Reporting Services documentation that may guide users briefly how to use Aspose.BarCode for performing different tasks like the followings. - QR or Micro QR Barcode Encoding Selector: https://docs.aspose.com/display/barcodereportingservices/QR+or+Micro+QR+Barcode+Encoding+Selector - How to Display BarCodes in Report Header: http://www.aspose.com/docs/display/barcodereportingservices/How+to+Display+BarCodes+in+Report+Header Overview: Aspose.BarCode for Reporting Services Aspose.BarCode for Reporting Services is a .NET solution for the rendering of barcode images in SQL Server 2000, 2005 & 2008 Reporting Services. It supports 40+ linear (1D) and 2D barcode symbologies including MacroPdf417, Australia Post, OneCode, Code128, Code39, PDF417, UPCA, Codabar, MSI and QR etc. Also render barcode images on reports in BMP, JPG, PNG and GIF formats. Other features include EAN-128 application identifiers, DPI resolution settings, barcode size and location adjustments. More about Aspose.BarCode for Reporting Services - Homepage of Aspose.BarCode for Reporting Services: http://www.aspose.com/products/barcode/reporting-services - Download Aspose.BarCode for Reporting Services: http://www.aspose.com/downloads/barcode/reportingservices - Online documentation of Aspose.BarCode for Reporting Services : http://docs.aspose.com/display/barcodereportingservices/Home Contact Information Aspose Pty Ltd Suite 163, 79 Longueville Road Lane Cove, NSW, 2066 Australia http://www.aspose.com/ email@example.com Phone: 888.277.6734 Fax: 866.810.9465 Lane Cove, Australia, May 12, 2017 --( PR.com )-- What's New in this Release?We are happy to announce the new release of Aspose.BarCode for Reporting Services 17.4.0. The major development in this release is the enhanced functionality of GS1 coded barcode. More often it is seem that GS1 code text contains complex combination of digits and letters. With Aspose.BarCode for SSRS 17.4, parsing and validation of those complex combinations is possible. Aspose.BarCode for SSRS allows developers to generate GS1 coded barcode according to AI (Application Identifier) specifications. New validators have been incorporated that can validate text code having only digits and complex AIs (combination of digits & letters). API will throw an exception in case it fails to validate. According to AI specification (ref: 703 AI, with letters – 324a, with more than 4 symbols) code text “(703)123” is incorrect. Aspose.BarCode will throw following exception if user tries to generate the barcode with EncodeTypes as GS1Code128. The following exception message will be displayed for such an incorrect barcode. Functionality of ExportToXml method has been improved. ExportToXml method now export dimension properties along with other properties of the newly define barcode into XML file. Below is the list of new and improved features added in this new release.• Improve GS1 parsing and validation• BarCodeBuilder allows to generate incorrect GS1 barcodes• Barcode generator accepts incorrect GS1 codetext• BarCodeBuilder.ExportToXml method is not exporting dimensions of the barcode in the XML file• Reorganize properties in Properties WindowNewly added documentation pages and articlesSome new tips and articles have now been added into Aspose.BarCode for Reporting Services documentation that may guide users briefly how to use Aspose.BarCode for performing different tasks like the followings.- QR or Micro QR Barcode Encoding Selector: https://docs.aspose.com/display/barcodereportingservices/QR+or+Micro+QR+Barcode+Encoding+Selector- How to Display BarCodes in Report Header: http://www.aspose.com/docs/display/barcodereportingservices/How+to+Display+BarCodes+in+Report+HeaderOverview: Aspose.BarCode for Reporting ServicesAspose.BarCode for Reporting Services is a .NET solution for the rendering of barcode images in SQL Server 2000, 2005 & 2008 Reporting Services. It supports 40+ linear (1D) and 2D barcode symbologies including MacroPdf417, Australia Post, OneCode, Code128, Code39, PDF417, UPCA, Codabar, MSI and QR etc. Also render barcode images on reports in BMP, JPG, PNG and GIF formats. Other features include EAN-128 application identifiers, DPI resolution settings, barcode size and location adjustments.More about Aspose.BarCode for Reporting Services- Homepage of Aspose.BarCode for Reporting Services: http://www.aspose.com/products/barcode/reporting-services- Download Aspose.BarCode for Reporting Services: http://www.aspose.com/downloads/barcode/reportingservices- Online documentation of Aspose.BarCode for Reporting Services : http://docs.aspose.com/display/barcodereportingservices/HomeContact InformationAspose Pty LtdSuite 163, 79 Longueville RoadLane Cove, NSW, 2066Australiahttp://firstname.lastname@example.orgPhone: 888.277.6734Fax: 866.810.9465 Click here to view the list of recent Press Releases from Aspose Pty Ltd
News Article | May 15, 2017
HONG KONG--(BUSINESS WIRE)--Motorola Solutions (NYI:MSI) will unveil highly advanced technology solutions to enhance the capabilities of nationwide public safety networks in the Asia Pacific at Critical Communications World 2017. The company’s mission-critical radio technologies, specialised software, mission critical broadband, command centre solutions and future innovation concepts will all be presented at Asia World Expo in Hong Kong. Motorola Solutions’ advanced technology showcase comes at a time when both mission-critical radio and public safety broadband solutions are in high demand throughout the Asia Pacific. This is reflected in forecasts that by 2020 there will be *almost 20 million active two-way radios in the region, while the ** North America and Asia Pacific regions combined will account for nearly 70 percent of all public safety broadband investment globally. Iain Clarke, corporate vice president and general manager, Asia Pacific, for Motorola Solutions, said the growth in both mission-critical communications and mobile broadband technologies is fuelled by demand for end-to-end, interoperable solutions combining the most needed elements of voice, data and multimedia communication. “ Public safety customers in Asia Pacific are among the most technically advanced in the world and are continuing their rapid adoption of mission-critical mobile intelligence services and smart technologies,” Clarke said. “ This is enabling them to filter and analyse the vast amounts of data available today so they can make better and faster decisions to protect our communities. “ Motorola Solutions’ deep domain expertise in delivering holistic public safety solutions will benefit those countries in Asia Pacific planning for large-scale, highly-available and secure deployments,” he said. Motorola Solutions continues to invest in new capabilities and skills to accelerate innovation within Asia Pacific - from its partnership with Singapore’s ST Electronics to develop advanced communications technologies to its acquisition of a large team of mobile application developers through the acquisition of Gridstone in Australia. Clarke said further evidence of his company’s much needed role in delivering secure and reliable critical communication services and global innovation was demonstrated through a series of major milestones. These include Motorola Solutions’: Motorola Solutions supports mission-critical systems in more than 20 countries globally including Hong Kong, Korea, Singapore, Australia, the U.S., the U.K. and countries in Europe. It also has a proven track record of delivering, managing and operating large-scale, complex and dependable public safety networks. “ At CCW we will demonstrate our broad capabilities to deliver end-to-end public safety software solutions as well as the powerful set of tools we have to enable organisations to work more safely and collaboratively with increased situational awareness,” Clarke said. Learn more about WAVE 5000 Learn more about the Si Series Learn more about CommandCentral Vault Learn more about Intelligent Middleware Motorola Solutions (NYSE: MSI) creates innovative, mission-critical communication solutions and services that help public safety and commercial customers build safer cities and thriving communities. For ongoing news, visit www.motorolasolutions.com/newsroom or subscribe to a news feed. * The number of active two-way radios in Asia Pacific is expected to increase to over 19.8 million by end 2020 (a CAGR growth of 3 percent from 2016-2020). Source: IHS Research ** The North America and Asia Pacific regions will account for nearly 70% of all public safety LTE investments over the next four years. Source: SNS Telecom report ‘Public Safety LTE & Mobile Broadband Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2017 Motorola Solutions, Inc. All rights reserved.
News Article | May 11, 2017
On Wednesday, shares in Hanover, Maryland headquartered Ciena Corp. recorded a trading volume of 2.47 million shares. The stock ended at $23.64, climbing 0.68% from the last trading session. The Company's shares have gained 7.80% in the last one month. The stock is trading above its 50-day and 200-day moving averages by 1.41% and 4.51%, respectively. Furthermore, shares of Ciena, which provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide, have a Relative Strength Index (RSI) of 64.96. On April 19th, 2017, Ciena announced that Globecomm has deployed the Company's converged packet-optical and packet networking solutions to meet growing content distribution requirements for a variety of critical applications, including video for breaking news stories, disaster recovery for armed forces, and essential connectivity to maritime ships crossing oceans around the world. With this network, Globecomm can cost-effectively increase the capacity, reliability, and availability of high-bandwidth services to more than 250 customers throughout its global footprint. Access our complete research report on CIEN for free at: Sunnyvale, California headquartered Infinera Corp.'s stock finished yesterday's session 0.94% lower at $9.49 with a total trading volume of 1.25 million shares. The Company's shares have gained 3.38% over the previous three months and 11.78% on an YTD basis. The stock is trading above its 200-day moving average by 2.03%. Furthermore, shares of Infinera, which provides optical transport networking equipment, software, and services worldwide, have an RSI of 43.10. On May 09th, 2017, Infinera announced a successful subsea field test with Canalink across its subsea cable. The test, conducted with the Infinera Infinite Capacity Engine, and featuring the Company's fourth-generation photonic integrated circuit, demonstrated the capability to upgrade the cable capacity 13-fold. The complimentary research report on INFN can be downloaded at: At the close of trading on Wednesday, shares in Suwanee, Georgia headquartered ARRIS International PLC rose 0.53%, ending the day at $28.19. The stock recorded a trading volume of 1.44 million shares. The Company's shares have advanced 5.86% in the last one month. The stock is trading 8.21% and 0.85% above its 50-day and 200-day moving averages, respectively. Moreover, shares of ARRIS International, which together with its subsidiaries, provides media entertainment and data communications solutions in the US and internationally, have an RSI of 73.31. On April 24th, 2017, ARRIS International announced two, new advanced Satellite Receiver solutions for satellite distribution networks: the DSR-7412 Integrated Receiver/Transcoder and DSR-4470 Integrated Receiver/Decoder. The new receivers feature next-generation HEVC UHD/4K decoding and DVB-S2X demodulation capabilities, adding to the Company's leading portfolio of satellite distribution solutions. Register for free on Stock-Callers.com and get access to the latest PDF format report on ARRS at: Chicago, Illinois headquartered Motorola Solutions Inc.'s shares ended the day 1.18% higher at $85.77. A total volume of 1.26 million shares was traded, which was above their three months average volume of 1.13 million shares. The stock has gained 2.46% in the last month, 10.24% over the previous three months, and 4.07% on an YTD basis. The Company's shares are trading 2.67% above their 50-day moving average and 8.92% above their 200-day moving average. Additionally, shares of Motorola Solutions, which provides mission-critical communication infrastructure, devices, accessories, software, and services in North America, Latin America, Asia/Pacific, Middle/East, Europe, and Africa, have an RSI of 57.79. On May 01st, 2017, Motorola Solutions announced that it has entered into an agreement to acquire Kodiak Networks, a privately held provider of broadband push-to-talk for commercial customers. The acquisition agreement is subject to customary closing conditions and is expected to close later this year. Download your free research report on MSI at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
News Article | April 18, 2017
HTC is trying to win potential customers from the competition by offering package deals and financing for VR-ready PCs (Credit: Will Shanklin/New Atlas) A PC-powered headset is a must for premium virtual reality experiences. The companies behind the two leading headsets – the HTC Vive and the Oculus Rift – are battling for early adopters by lowering the barriers to obtaining a VR-capable PC. Today, HTC announced package deals to woo potential customers. HTC announced three offers. The first bundles an NVIDIA GeForce GTX 1070 Founders Edition graphics card with a Vive headset for US$1,000 (or financed at $49 per month for 24 months). This offer runs until April 24 and represents a $200 savings from the suggested retail price for both. It should be ideal for individuals that already have a capable PC which needs only a powerful graphics card to become VR-ready. HTC is also launching a second bundle with an MSI VR-ready laptop and Vive headset/controllers. The full retail price is $2,498, or if financed, about $125 per month over two years. The MSI GS73VR has a 17.3-inch display, Intel core i7 processor, an NVIDIA GeForce GTX 1060 graphics card and 16 GB of RAM. Lastly, there is a desktop bundle which pairs the Vive with a Cyberpower GXi970, available financed for less than $99 per month for two years. The GXi970 includes an Intel core i5 processor, an NVIDIA GeForce GTX 1070 graphics card and 8 GB of RAM. While HTC has mostly tried to win potential customers over with discounts and financing, the competition is stiff: Oculus has not only given the Rift a permanent price drop, it has also taken steps to lower the minimum requirements for Rift-ready PCs.
News Article | June 3, 2017
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced interim data from CheckMate -142, a Phase 2, multi-cohort trial evaluating Opdivo (nivolumab) monotherapy or in combination with Yervoy (ipilimumab) for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC). These results from the Opdivo and Yervoy combination cohort of the trial included 84 patients who received their first dose at least 6 months prior to analysis. The primary endpoint of investigator-assessed objective response rate (ORR) was 54.8% (95% CI: 43.5, 65.7). Responses were sustained up to 15.9 months and 85% of responses were ongoing; median duration of response was not yet reached. The 9-month overall survival (OS) rate was 87.6% (95% CI: 78.1, 93.1) and median OS had not been reached at the time of analysis. The safety profile of the Opdivo plus Yervoy combination included 28.6% of patients with Grade 3/4 treatment-related adverse events (AEs). These data from Abstract #3531 will be presented today from 8:00–11:30 AM CDT in Hall A at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017. “The clinically meaningful survival and response data for patients with dMMR or MSI-H colorectal cancer treated with Opdivo in combination with Yervoy are very promising,” said Thierry Andre, M.D., Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris. “These interim data are important as they build on the study results observed with Opdivo monotherapy in these patients and show the potential of an Immuno-Oncology combination in this advanced type of colorectal cancer for which there is a significant unmet need.” When the proteins that repair mismatch errors in DNA replication are missing or non-functional, dMMR occurs, and leads to MSI-H tumors in certain types of cancer, including CRC. Approximately 5% of metastatic CRC patients have dMMR or MSI-H biomarkers, and these patients are less likely to benefit from conventional chemotherapy than patients whose tumors are mismatch repair proficient. “Through our robust Immuno-Oncology research and development efforts, we are investigating predictive biomarkers like dMMR or MSI-H with the goal of tailoring treatment approaches that provide the maximum benefit for individual patients,” said Ian M. Waxman, M.D., development lead, Gastrointestinal Cancers, Bristol-Myers Squibb. “We are encouraged by these interim results for Opdivo plus Yervoy, and we look forward to further evaluating the efficacy and safety of our Immuno-Oncology combination therapies in metastatic colorectal cancer, as well as across a broad range of other tumor types.” CheckMate -142 is an international Phase 2, multi-cohort, open-label, non-comparative trial evaluating Opdivo monotherapy or in combination with Yervoy in previously treated recurrent or metastatic colorectal cancer (CRC), including patients with and without DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). In results from the Opdivo monotherapy cohort presented at the 2017 Gastrointestinal Cancers Symposium, the investigator-assessed objective response rate (ORR) was 31.1% and the 12 month overall survival (OS) rate was 73.8%. In this cohort, Opdivo was well tolerated with a safety profile consistent with that reported in other solid tumors and no new safety signals were observed. In the combination cohort, the primary endpoint is investigator-assessed ORR using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Other key endpoints included ORR by blinded independent central review (BICR), progression-free survival (PFS), OS and safety. Patients were treated with Opdivo (3 mg/kg) and Yervoy (1 mg/kg) every three weeks for four doses then Opdivo every two weeks until disease progression, death or unacceptable toxicity. Of the 84 patients treated, 78% had two or more prior lines of therapy. Treatment-related adverse events (AEs) of any grade occurred in 67.9% of patients. Treatment-related AEs were managed, with 13.1% of patients discontinuing treatment. The most common AEs of any grade occurring in ≥10% of MSI-H patients were diarrhea (23.8%), fatigue (16.7%), aspartate aminotransferase increase (16.7%), pyrexia (15.5%), pruritus (15.5%), alanine aminotransferase increase (14.3%), nausea (14.3%), hyperthyroidism (13.1%) and hypothyroidism (13.1%). Grade 3/4 AEs occurred in 28.6% of patients. No treatment-related deaths were reported. About Colorectal Cancer and dMMR or MSI-H Colorectal Cancer Colorectal cancer (CRC) is cancer that develops in the colon or the rectum, which are parts of the body’s digestive or gastrointestinal system. Colorectal cancer is the third most common form of cancer, with a worldwide incidence of 1.4 million cases, and is the fourth most common cause of cancer deaths. In the U.S., CRC is the second leading cause of cancer-related deaths among men and women combined, with more than 135,000 new cases expected to be diagnosed annually. DNA mismatch repair deficiency (dMMR) occurs when the proteins that repair mismatch errors in DNA replication are missing or non-functional, which leads to microsatellite instability-high (MSI-H) tumors in certain types of cancer, including CRC. Approximately 15% of CRC patients and 5% of metastatic CRC patients have dMMR or MSI-H biomarkers. Patients with dMMR or MSI-H metastatic CRC are less likely to benefit from conventional chemotherapy and typically have a poor prognosis, with lower survival rates on conventional chemotherapy than patients whose tumors are mismatch repair proficient. Routine testing to confirm dMMR or MSI-H status should be conducted for all CRC patients. At Bristol-Myers Squibb, patients are at the center of everything we do. Our vision for the future of cancer care is focused on researching and developing transformational Immuno-Oncology (I-O) medicines for hard-to-treat cancers that could potentially improve outcomes for these patients. We are leading the scientific understanding of I-O through our extensive portfolio of investigational compounds and approved agents. Our differentiated clinical development program is studying broad patient populations across more than 50 types of cancers with 14 clinical-stage molecules designed to target different immune system pathways. Our deep expertise and innovative clinical trial designs position us to advance I-O/I-O, I-O/chemotherapy, I-O/targeted therapies and I-O/radiation therapies across multiple tumors and potentially deliver the next wave of therapies with a sense of urgency. We also continue to pioneer research that will help facilitate a deeper understanding of the role of immune biomarkers and how patients’ individual tumor biology can be used as a guide for treatment decisions throughout their journey. We understand making the promise of I-O a reality for the many patients who may benefit from these therapies requires not only innovation on our part but also close collaboration with leading experts in the field. Our partnerships with academia, government, advocacy and biotech companies support our collective goal of providing new treatment options to advance the standards of clinical practice. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. Opdivo’s leading global development program is based on Bristol-Myers Squibb’s scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has enrolled more than 25,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression. In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 60 countries, including the United States, the European Union and Japan. In October 2015, the company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union. OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. OPDIVO® (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. OPDIVO® (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. OPDIVO® (nivolumab) is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. OPDIVO® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. YERVOY can result in severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. The majority of these immune-mediated reactions initially manifested during treatment; however, a minority occurred weeks to months after discontinuation of YERVOY. Assess patients for signs and symptoms of enterocolitis, dermatitis, neuropathy, and endocrinopathy and evaluate clinical chemistries including liver function tests (LFTs), adrenocorticotropic hormone (ACTH) level, and thyroid function tests at baseline and before each dose. OPDIVO can cause immune-mediated pneumonitis. Fatal cases have been reported. Monitor patients for signs with radiographic imaging and for symptoms of pneumonitis. Administer corticosteroids for Grade 2 or more severe pneumonitis. Permanently discontinue for Grade 3 or 4 and withhold until resolution for Grade 2. In patients receiving OPDIVO monotherapy, fatal cases of immune-mediated pneumonitis have occurred. Immune-mediated pneumonitis occurred in 3.1% (61/1994) of patients. In patients receiving OPDIVO with YERVOY, immune-mediated pneumonitis occurred in 6% (25/407) of patients. In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving OPDIVO: Grade 3 (n=1) and Grade 2 (n=12). OPDIVO can cause immune-mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 (of more than 5 days duration), 3, or 4 colitis. Withhold OPDIVO monotherapy for Grade 2 or 3 and permanently discontinue for Grade 4 or recurrent colitis upon re-initiation of OPDIVO. When administered with YERVOY, withhold OPDIVO and YERVOY for Grade 2 and permanently discontinue for Grade 3 or 4 or recurrent colitis. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients. In patients receiving OPDIVO with YERVOY, immune-mediated colitis occurred in 26% (107/407) of patients including three fatal cases. In a separate Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening, or fatal (diarrhea of ≥7 stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) patients. Across all YERVOY-treated patients in that study (n=511), 5 (1%) developed intestinal perforation, 4 (0.8%) died as a result of complications, and 26 (5%) were hospitalized for severe enterocolitis. OPDIVO can cause immune-mediated hepatitis. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater transaminase elevations. Withhold for Grade 2 and permanently discontinue for Grade 3 or 4 immune-mediated hepatitis. In patients receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients. In patients receiving OPDIVO with YERVOY, immune-mediated hepatitis occurred in 13% (51/407) of patients. In a separate Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations >5x the ULN or total bilirubin elevations >3x the ULN; Grade 3-5) occurred in 8 (2%) patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4%. In a separate Phase 3 study of YERVOY 3 mg/kg, 1 case of fatal Guillain-Barré syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported. OPDIVO can cause immune-mediated hypophysitis, immune-mediated adrenal insufficiency, autoimmune thyroid disorders, and Type 1 diabetes mellitus. Monitor patients for signs and symptoms of hypophysitis, signs and symptoms of adrenal insufficiency, thyroid function prior to and periodically during treatment, and hyperglycemia. Administer hormone replacement as clinically indicated and corticosteroids for Grade 2 or greater hypophysitis. Withhold for Grade 2 or 3 and permanently discontinue for Grade 4 hypophysitis. Administer corticosteroids for Grade 3 or 4 adrenal insufficiency. Withhold for Grade 2 and permanently discontinue for Grade 3 or 4 adrenal insufficiency. Administer hormone-replacement therapy for hypothyroidism. Initiate medical management for control of hyperthyroidism. Withhold OPDIVO for Grade 3 and permanently discontinue for Grade 4 hyperglycemia. In patients receiving OPDIVO monotherapy, hypophysitis occurred in 0.6% (12/1994) of patients. In patients receiving OPDIVO with YERVOY, hypophysitis occurred in 9% (36/407) of patients. In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred in 1% (20/1994) of patients. In patients receiving OPDIVO with YERVOY, adrenal insufficiency occurred in 5% (21/407) of patients. In patients receiving OPDIVO monotherapy, hypothyroidism or thyroiditis resulting in hypothyroidism occurred in 9% (171/1994) of patients. Hyperthyroidism occurred in 2.7% (54/1994) of patients receiving OPDIVO monotherapy. In patients receiving OPDIVO with YERVOY, hypothyroidism or thyroiditis resulting in hypothyroidism occurred in 22% (89/407) of patients. Hyperthyroidism occurred in 8% (34/407) of patients receiving OPDIVO with YERVOY. In patients receiving OPDIVO monotherapy, diabetes occurred in 0.9% (17/1994) of patients. In patients receiving OPDIVO with YERVOY, diabetes occurred in 1.5% (6/407) of patients. In a separate Phase 3 study of YERVOY 3 mg/kg, severe to life-threatening immune-mediated endocrinopathies (requiring hospitalization, urgent medical intervention, or interfering with activities of daily living; Grade 3-4) occurred in 9 (1.8%) patients. All 9 patients had hypopituitarism, and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism. 6 of the 9 patients were hospitalized for severe endocrinopathies. OPDIVO can cause immune-mediated nephritis. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Administer corticosteroids for Grades 2-4 increased serum creatinine. Withhold OPDIVO for Grade 2 or 3 and permanently discontinue for Grade 4 increased serum creatinine. In patients receiving OPDIVO monotherapy, immune-mediated nephritis and renal dysfunction occurred in 1.2% (23/1994) of patients. In patients receiving OPDIVO with YERVOY, immune-mediated nephritis and renal dysfunction occurred in 2.2% (9/407) of patients. OPDIVO can cause immune-mediated rash, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some cases with fatal outcome. Administer corticosteroids for Grade 3 or 4 rash. Withhold for Grade 3 and permanently discontinue for Grade 4 rash. For symptoms or signs of SJS or TEN, withhold OPDIVO and refer the patient for specialized care for assessment and treatment; if confirmed, permanently discontinue. In patients receiving OPDIVO monotherapy, immune-mediated rash occurred in 9% (171/1994) of patients. In patients receiving OPDIVO with YERVOY, immune-mediated rash occurred in 22.6% (92/407) of patients. In a separate Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) patients. 1 (0.2%) patient died as a result of toxic epidermal necrolysis. 1 additional patient required hospitalization for severe dermatitis. OPDIVO can cause immune-mediated encephalitis. Evaluation of patients with neurologic symptoms may include, but not be limited to, consultation with a neurologist, brain MRI, and lumbar puncture. Withhold OPDIVO in patients with new-onset moderate to severe neurologic signs or symptoms and evaluate to rule out other causes. If other etiologies are ruled out, administer corticosteroids and permanently discontinue OPDIVO for immune-mediated encephalitis. In patients receiving OPDIVO monotherapy, encephalitis occurred in 0.2% (3/1994) of patients. Fatal limbic encephalitis occurred in one patient after 7.2 months of exposure despite discontinuation of OPDIVO and administration of corticosteroids. Encephalitis occurred in one patient receiving OPDIVO with YERVOY (0.2%) after 1.7 months of exposure. Based on the severity of adverse reaction, permanently discontinue or withhold treatment, administer high-dose corticosteroids, and, if appropriate, initiate hormone-replacement therapy. Across clinical trials of OPDIVO the following clinically significant immune-mediated adverse reactions occurred in <1.0% of patients receiving OPDIVO: uveitis, iritis, pancreatitis, facial and abducens nerve paresis, demyelination, polymyalgia rheumatica, autoimmune neuropathy, Guillain-Barré syndrome, hypopituitarism, systemic inflammatory response syndrome, gastritis, duodenitis, sarcoidosis, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), myositis, myocarditis, rhabdomyolysis, motor dysfunction, vasculitis, and myasthenic syndrome. OPDIVO can cause severe infusion reactions, which have been reported in <1.0% of patients in clinical trials. Discontinue OPDIVO in patients with Grade 3 or 4 infusion reactions. Interrupt or slow the rate of infusion in patients with Grade 1 or 2. In patients receiving OPDIVO monotherapy, infusion-related reactions occurred in 6.4% (127/1994) of patients. In patients receiving OPDIVO with YERVOY, infusion-related reactions occurred in 2.5% (10/407) of patients. Complications, including fatal events, occurred in patients who received allogeneic HSCT after OPDIVO. Outcomes were evaluated in 17 patients from Checkmate 205 and 039, who underwent allogeneic HSCT after discontinuing OPDIVO (15 with reduced-intensity conditioning, 2 with myeloablative conditioning). Thirty-five percent (6/17) of patients died from complications of allogeneic HSCT after OPDIVO. Five deaths occurred in the setting of severe or refractory GVHD. Grade 3 or higher acute GVHD was reported in 29% (5/17) of patients. Hyperacute GVHD was reported in 20% (n=2) of patients. A steroid-requiring febrile syndrome, without an identified infectious cause, was reported in 35% (n=6) of patients. Two cases of encephalitis were reported: Grade 3 (n=1) lymphocytic encephalitis without an identified infectious cause, and Grade 3 (n=1) suspected viral encephalitis. Hepatic veno-occlusive disease (VOD) occurred in one patient, who received reduced-intensity conditioned allogeneic HSCT and died of GVHD and multi-organ failure. Other cases of hepatic VOD after reduced-intensity conditioned allogeneic HSCT have also been reported in patients with lymphoma who received a PD-1 receptor blocking antibody before transplantation. Cases of fatal hyperacute GVHD have also been reported. These complications may occur despite intervening therapy between PD-1 blockade and allogeneic HSCT. Follow patients closely for early evidence of transplant-related complications such as hyperacute GVHD, severe (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic VOD, and other immune-mediated adverse reactions, and intervene promptly. Based on their mechanisms of action, OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with an OPDIVO- or YERVOY- containing regimen and for at least 5 months after the last dose of OPDIVO. It is not known whether OPDIVO or YERVOY is present in human milk. Because many drugs, including antibodies, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from an OPDIVO-containing regimen, advise women to discontinue breastfeeding during treatment. Advise women to discontinue nursing during treatment with YERVOY and for 3 months following the final dose. In Checkmate 037, serious adverse reactions occurred in 41% of patients receiving OPDIVO (n=268). Grade 3 and 4 adverse reactions occurred in 42% of patients receiving OPDIVO . The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to <5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066, serious adverse reactions occurred in 36% of patients receiving OPDIVO (n=206). Grade 3 and 4 adverse reactions occurred in 41% of patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse reactions reported in ≥2% of patients receiving OPDIVO were gamma-glutamyltransferase increase (3.9%) and diarrhea (3.4%). In Checkmate 067, serious adverse reactions (73% and 37%), adverse reactions leading to permanent discontinuation (43% and 14%) or to dosing delays (55% and 28%), and Grade 3 or 4 adverse reactions (72% and 44%) all occurred more frequently in the OPDIVO plus YERVOY arm (n=313) relative to the OPDIVO arm (n=313). The most frequent (≥10%) serious adverse reactions in the OPDIVO plus YERVOY arm and the OPDIVO arm, respectively, were diarrhea (13% and 2.6%), colitis (10% and 1.6%), and pyrexia (10% and 0.6%). In Checkmate 017 and 057, serious adverse reactions occurred in 46% of patients receiving OPDIVO (n=418). The most frequent serious adverse reactions reported in at least 2% of patients receiving OPDIVO were pneumonia, pulmonary embolism, dyspnea, pyrexia, pleural effusion, pneumonitis, and respiratory failure. In Checkmate 025, serious adverse reactions occurred in 47% of patients receiving OPDIVO (n=406). The most frequent serious adverse reactions reported in ≥2% of patients were acute kidney injury, pleural effusion, pneumonia, diarrhea, and hypercalcemia. In Checkmate 205 and 039, adverse reactions leading to discontinuation occurred in 7% and dose delays due to adverse reactions occurred in 34% of patients (n=266). Serious adverse reactions occurred in 26% of patients. The most frequent serious adverse reactions reported in ≥1% of patients were pneumonia, infusion-related reaction, pyrexia, colitis or diarrhea, pleural effusion, pneumonitis, and rash. Eleven patients died from causes other than disease progression: 3 from adverse reactions within 30 days of the last OPDIVO dose, 2 from infection 8 to 9 months after completing OPDIVO, and 6 from complications of allogeneic HSCT. In Checkmate 141, serious adverse reactions occurred in 49% of patients receiving OPDIVO. The most frequent serious adverse reactions reported in at least 2% of patients receiving OPDIVO were pneumonia, dyspnea, respiratory failure, respiratory tract infection, and sepsis. In Checkmate 275, serious adverse reactions occurred in 54% of patients receiving OPDIVO (n=270). The most frequent serious adverse reactions reported in at least 2% of patients receiving OPDIVO were urinary tract infection, sepsis, diarrhea, small intestine obstruction, and general physical health deterioration. In Checkmate 037, the most common adverse reaction (≥20%) reported with OPDIVO (n=268) was rash (21%). In Checkmate 066, the most common adverse reactions (≥20%) reported with OPDIVO (n=206) vs dacarbazine (n=205) were fatigue (49% vs 39%), musculoskeletal pain (32% vs 25%), rash (28% vs 12%), and pruritus (23% vs 12%). In Checkmate 067, the most common (≥20%) adverse reactions in the OPDIVO plus YERVOY arm (n=313) were fatigue (59%), rash (53%), diarrhea (52%), nausea (40%), pyrexia (37%), vomiting (28%), and dyspnea (20%). The most common (≥20%) adverse reactions in the OPDIVO (n=313) arm were fatigue (53%), rash (40%), diarrhea (31%), and nausea (28%). In Checkmate 017 and 057, the most common adverse reactions (≥20%) in patients receiving OPDIVO (n=418) were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite. In Checkmate 025, the most common adverse reactions (≥20%) reported in patients receiving OPDIVO (n=406) vs everolimus (n=397) were asthenic conditions (56% vs 57%), cough (34% vs 38%), nausea (28% vs 29%), rash (28% vs 36%), dyspnea (27% vs 31%), diarrhea (25% vs 32%), constipation (23% vs 18%), decreased appetite (23% vs 30%), back pain (21% vs 16%), and arthralgia (20% vs 14%). In Checkmate 205 and 039, the most common adverse reactions (≥20%) reported in patients receiving OPDIVO (n=266) were upper respiratory tract infection (44%), fatigue (39%), cough (36%), diarrhea (33%), pyrexia (29%), musculoskeletal pain (26%), rash (24%), nausea (20%) and pruritus (20%). In Checkmate 141, the most common adverse reactions (≥10%) in patients receiving OPDIVO were cough and dyspnea at a higher incidence than investigator’s choice. In Checkmate 275, the most common adverse reactions (≥ 20%) reported in patients receiving OPDIVO (n=270) were fatigue (46%), musculoskeletal pain (30%), nausea (22%), and decreased appetite (22%). In a separate Phase 3 study of YERVOY 3 mg/kg, the most common adverse reactions (≥5%) in patients who received YERVOY at 3 mg/kg were fatigue (41%), diarrhea (32%), pruritus (31%), rash (29%), and colitis (8%). Please see U.S. Full Prescribing Information for OPDIVO and YERVOY, including Boxed WARNING regarding immune-mediated adverse reactions for YERVOY. About the Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Collaboration In 2011, through a collaboration agreement with Ono Pharmaceutical Co., Ltd (Ono), Bristol-Myers Squibb expanded its territorial rights to develop and commercialize Opdivo globally except in Japan, South Korea and Taiwan, where Ono had retained all rights to the compound at the time. On July 23, 2014, Bristol-Myers Squibb and Ono further expanded the companies’ strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies – as single agents and combination regimens – for patients with cancer in Japan, South Korea and Taiwan. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook. This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that Opdivo or Yervoy will receive regulatory approval for an additional indication. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2016, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
News Article | July 26, 2017
Bottom Line: Molecular classification of the four distinct subtypes of gastric cancer could potentially shape tailored treatment options by helping to predict survival outcomes and patients' response to chemotherapy. Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research. Author: Ju-Seog Lee, PhD, an associate professor in the Department of Systems Biology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. Background: In 2014, The Cancer Genome Atlas (TCGA) project discovered that there are four molecular subtypes of gastric cancer: Epstein-Barr virus subtype (EBV); microsatellite instability subtype (MSI); genomically stable subtype (GS); and chromosomal instability subtype (CIN). Lee said most patients with early-stage gastric cancer are treated with a surgical resection, followed by chemotherapy. "However, outcomes vary significantly, and that difference in clinical outcomes is likely due to biological and molecular differences in tumors. These differences have not been fully understood." How the Study Was Conducted and Results: In order to identify the clinical significance of the four subtypes, Lee and colleagues re-analyzed gene expression data for these subtypes using data from the gastric cancer cohort of the TCGA project. They used that data to develop prediction models and tested the models in two independent cohorts of 267 and 432 gastric cancer patients, respectively, in South Korea and at MD Anderson. Overall, they found that the EBV subtype was associated with the best prognosis for both recurrence-free survival (RFS) and overall survival, and the GS subtype was associated with the worst prognosis. The MSI subtype was associated with a moderate prognosis. The CIN subtype was also associated with moderate prognosis, but poorer in the South Korean cohort than in the MD Anderson cohort. Lee said this suggests that the CIN subtype may be less homogeneous and therefore harder to characterize. The study also sought to examine whether specific subtypes of gastric cancer were associated with a clinical benefit from adjuvant chemotherapy. The researchers based this part of the study solely on the MD Anderson cohort, because more than half of them had received adjuvant chemotherapy, compared with a smaller segment of the South Korean population. This portion of the study indicated that patients with the CIN subtype received the greatest benefit from chemotherapy; the three-year RFS rate was 58.7 percent for those who had received chemotherapy, compared with 33.5 percent for those who had not. Patients with the GS subtype showed no benefit, while those with the MSI subtype showed a moderate benefit. The effects of chemotherapy on patients with the EBV subtype could not be assessed, because all the patients had received it, leaving no basis for comparison. Author Comment: Lee said the failure of the GS subtype to respond to chemotherapy was one of the study's most intriguing findings. "This means that we need to find novel targets and drugs for this subtype," Lee said, adding that patients with the GS subtype could now potentially be spared the damaging side effects of chemotherapy that will most likely not work. Lee said the study's results indicate that classifying gastric cancer cases according to subtype could provide guidance to physicians as they try to determine the best treatment option for a particular patient. "These findings, if confirmed, could provide some information for personalized medicine," Lee said. "As we learn more about the biological characteristics associated with each subtype, it will help determine which patients will benefit from immunotherapy, chemotherapy, or other treatment options." Limitations: Lee said the primary limitation of the study is that data were collected retrospectively. Further research would be necessary to confirm the findings in a prospective study setting. Disclosures: This study was funded by grants from the National Institutes of Health, The University of Texas MD Anderson Cancer Center, the Korea National Research Foundation, the Scientific Research Center Program; and the Korean Research Institute of Bioscience and Biotechnology. Lee declares no conflicts of interest. About the American Association for Cancer Research Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 21,900 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www. .
MSI Inc and Osaka University | Date: 2011-04-07
A distance measuring apparatus comprises: an edge specifying part 101 for specifying the edge of a probe 6 in a secondary portrait appearing on the surface of a work 9 and an image of the probe 6; a straight line inserting part 102 for inserting a straight line along the outer edge of the secondary portrait onto an image, and an overlap determining part 103 for determining an overlap of the edge and the straight line, wherein one or more LED lamps 7, and calculating part for calculating the distance wherein the imaging device and the probe 6 are movably held integrally for the surface of the work 9.
Osaka University and MSI Inc | Date: 2012-02-01
An ion source (10) is provided with a push-out electrode (1), a pull-out electrode (2), and a pull-in electrode (3) all for ionizing a sample and accelerating generated ions in a pulsed manner, wherein the push-out electrode (1) and/or the pull-in electrode (3) has a curved surface shape having a depression curved in the direction opposite to the direction of travel of the ions. As a result, a compact ion source capable of temporally and spatially focusing ions and outputting the ions, and a compact time-of-flight mass spectroscope with good detection resolution and detection sensitivity which is provided with the compact ion source can be provided.
News Article | February 15, 2017
M S International Inc. (“MSI”), North America’s Leading Supplier of Premium Surfacing Products, recently updated and expanded its Bay Area Showroom and Distribution Center. MSI has doubled the size of its Bay Area Showroom and Distribution Center. Today, it boasts more than 500 surfacing products displayed and inventoried throughout 5,600 sq. ft. of stunning showroom space and approximately 160,000 sq. ft. of total warehousing space. Impeccably styled, new displays and creative installs allow consumers to get hands-on with the products and easily envision them in their homes. New decorative mosaic fixtures further enhance the shopping experience, making it easier than ever to browse over 300 distinctive tiles. An additional 1,500 sq. ft. Q™ Premium Natural Quartz Slab Gallery was also installed — showcasing North America’s fastest growing line of quartz countertops, including several on-trend white and gray colors. Underscoring MSI’s commitment to customer service, the redesigned showroom includes new seating areas and work tables, as well as hosting space for seminars and various industry events. A spacious conference room provides a comfortable space for designers, fabricators, and staff to meet with customers. In addition to the showroom, the warehouse received substantial upgrades. Raj Shah, President of MSI explains, “We doubled the warehouse size, thereby significantly increasing our overall stocking capacity for all of our product lines including flooring, countertops and hardscaping. In addition, we installed four more cranes—bringing the total number to eight—to improve operational functionality and fill orders more efficiently.” Reflecting on the numerous enhancements, Shah adds, “Our Bay Area Showroom provides everyone from builders to homeowners with a state-of-the-art facility in which to explore our vast selection of traditional, contemporary, and trend-forward surfacing products. We look forward to serving the local market for years to come.” An open house is scheduled for March 16, 2017. The public is encouraged to stop by and learn about all the exciting new products MSI has to offer. For an immediate introduction to the updated facility, they’re invited to take a Google Tour. These advanced, 360-degree interactive virtual tours make it possible for consumers to browse the tile showroom, slab warehouse, Q™ Premium Natural Quartz Slab Gallery, and more — right from the comfort of their homes. The Bay Area Showroom is located at: 22300-B Hathaway Avenue Hayward, CA 94541 Phone: 510-921-5400 Founded in 1975, MSI is the leading supplier of Premium Surfaces including flooring, countertops, decorative mosaics and wall tile, and hardscaping products. MSI’s product offering includes an extensive selection of granite, marble, porcelain, ceramic, quartz, glass, quartzite, and other natural stone products. Headquartered in Orange, California, MSI also maintains distribution centers across the United States and Canada. MSI’s product line is imported from over 36 different countries on six continents bringing the very best products to the North American Market. The company maintains an inventory of over 125 million square feet of material. For more information on MSI, visit: http://www.msistone.com